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ABSTRACT 
Spontaneous itch and pain are the most common symptoms in various skin diseases, 
including allergic contact dermatitis (ACD). The chemokine (C-C motif) ligand 2 (CCL2, also 
referred to as monocyte chemoattractant protein 1 (MCP-1))and its receptor CCR2 are 
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involved in the pathophysiology of ACD, but little is known of the role of CCL2/CCR2 for 
the itch- and pain-behaviors accompanying the murine model of this disorder, termed contact 
hypersensitivity (CHS). C57BL/6 mice previously sensitized to the hapten, squaric acid 
dibutyl ester, applied to the abdomen were subsequently challenged twice with the hapten 
delivered to either the cheek or to the hairy skin of the hind paw resulting in CHS at that site. 
By 24 h after the 2
nd
 challenge to the hind paw CCL2 and CCR2 mRNA, protein, and 
signaling activity were upregulated in the dorsal root ganglion (DRG). Calcium imaging and 
whole-cell current-clamp recordings revealed that CCL2 directly acted on its neuronal 
receptor, CCR2 to activate a subset of small-diameter, nociceptive-like DRG neurons 
retrogradely labeled from the CHS site. Intradermal injection of CCL2 into the site of CHS on 
the cheek evoked site-directed itch- and pain-like behaviors which could be attenuated by 
prior delivery of an antagonist of CCR2. In contrast, CCL2 failed to elicit either type of 
behavior in control mice. Results are consistent with the hypothesis that CHS upregulates 
CCL2/CCR2 signaling in a subpopulation of cutaneous small diameter DRG neurons and that 
CCL2 can activate these neurons through neuronal CCR2 to elicit itch- and pain-behavior. 
Targeting the CCL2/CCR2 signaling might be beneficial for the treatment of the itch and pain 
sensations accompanying ACD in humans. 
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1. Introduction 
Allergic contact dermatitis (ACD) is one of the most common inflammatory diseases of 
  
the skin, as a hapten-induced type IV delayed hypersensitivity reaction, which is primarily 
mediated by dermal dendritic cells (DC) and T lymphocytes, involving multiple cytokines 
and chemokines(Christensen and Haase, 2012; Grabbe and Schwarz, 1998; Honda et al., 
2013; Sebastiani et al., 2002).  
The chemokine (C-C motif) ligand 2 (CCL2), a member of the C-C chemokine subfamily, 
is a potent attractant of memory T-cells(Carr et al., 1994; Loetscher et al., 1994), 
monocytes(Deshmane et al., 2009) and natural killer (NK) cells(Allavena et al., 1994). CCL2 
is involved in the pathophysiology of ACD in humans and the murine model of ACD, termed 
contact hypersensitivity (CHS). During the elicitation phase of ACD or CHS, CCL2 is the 
initial chemokine produced by activated resident skin cells such as keratinocytes, fibroblasts 
and endothelial cells preceding the infiltration of monocytes and lymphocytes. The 
infiltrating monocytes also serve as a secondary source of the chemokine(Goebeler et al., 
2001; Mitsui et al., 2003; Sebastiani et al., 2002; Yu et al., 1994). Transgenic mice with an 
increased expression of CCL2 exhibited enhanced inflammatory responses during CHS 
together with more infiltration of dendritic cells into the skin(Mizumoto et al., 2001; 
Nakamura et al., 1995). In contrast, a downregulation of CCL2 using the RNA interference 
strategy attenuated hapten-induced CHS(Ishimoto et al., 2008). 
Itch- and pain-related behaviors often accompany various skin diseases, including ACD in 
humans and CHS in mice(Buddenkotte and Steinhoff, 2010; LaMotte, 2016). Although the 
immune mechanisms of CHS have been intensively investigated, less is known of the itch 
and pain behaviors and their underlying neural mechanisms. CHS enhanced the excitability 
of cutaneous primary sensory neurons that mediate itch and pain(Qu et al., 2014). In addition, 
  
an associated upregulation of the chemokine receptor, CXCR3 in cutaneous neurons and 
responses to its ligand, CXCL10, suggested that this chemokine may contribute to itch 
associated with CHS(Qu et al., 2015).  
Though CCL2 and its receptor CCR2 are typically expressed in immune cells, both can be 
upregulated in sensory neurons in models of chronic neuropathic or inflammatory 
pain(Abbadie et al., 2003; Illias et al., 2018; Jung et al., 2008; Serrano et al., 2010; Sun et al., 
2006; Takeda et al., 2018; Tanaka et al., 2004; Thacker et al., 2009; White et al., 2005). 
Moreover, CCL2 can directly activate primary sensory neurons through neuronal CCR2 to 
exert its nociceptive effects(Serrano et al., 2010; Sun et al., 2006; Takeda et al., 2018; White 
et al., 2005). Although CCL2 plays an important role in the pathogenesis of ACD, a possible 
contribution of CCL2 to the itch- and pain-behaviors that accompany ACD has not been 
investigated.  
In the present study, we tested the direct effects of CCL2 on primary sensory neurons and 
explored the potential role of CCL2/CCR2 signaling in mediating allergic itch and pain using 
a murine model of ACD induced by the hapten, squaric acid dibutylester (SADBE). 
 
2. Material and methods 
2.1. Animals 
The mice used in the study were C57BL/6 males, 2 to 3 months of age and weighing 
20–30 g. The breeders used to develop our colonies of MRGPRA3 and MRGPRD transgenic 
mice were provided by Dr Xinzhong Dong’s laboratory (John Hopkins University). For one 
  
type of mouse, the green fluorescent protein (GFP) was in neurons that expressed the 
MRGPRA3 receptor (MrgprA3
+
 neurons)(Han et al., 2013b) whereas the other type of mouse 
exhibited the GFP in neurons that expressed the MRGPRD receptor (MrgprD
+
 
neurons)(Zylka et al., 2005). The experimental procedures were approved by the Institutional 
Animal Care and Use Committee of Yale University School of Medicine and were in 
accordance with the guidelines provided by the National Institute of Health and the 
International Association for the Study of Pain. 
2.2. Model of allergic contact dermatitis 
The mouse model of allergic contact dermatitis or CHS was elicited by the contact 
sensitizer squaric acid dibutylester (SADBE; Sigma, St. Louis, MO, USA)(Qu et al., 2014; 
Qu et al., 2015). “CHS” mice were first sensitized with 1% SADBE in acetone (25 µL) 
topically applied to the shaved abdomen once a day for three consecutive days. Five days 
later, mice were challenged with two daily applications of 1% SADBE in acetone (25 µL) 
either to the right cheek (cheek model for behavioral tests) or to the hairy skin of the calf and 
foot of one hind limb (calf model for in-vitro studies). Control mice received only acetone. 
2.3. Behavioral testing 
All behavioral tests were performed 24 hours after the second challenge with SADBE or 
acetone vehicle topically applied to the right cheek. The test chamber was equipped with four 
mirrors to provide a top view of all sides. Behavioral responses were video recorded by a 
camcorder. The video recording was subsequently played back offline in slow-motion to 
assess detailed measurements of scratching with the hind paw and wiping with the fore paw 
  
directed toward the challenge site. The total number of spontaneous scratching bouts and 
number of wipes were measured for 30 minutes(Shimada and LaMotte, 2008a). CCL2 (1 
µg/10 µL in PBS; R&D Systems, Minneapolis, MN, USA) or its vehicle alone (10 µL PBS) 
was injected intradermally into the right cheek in CHS mice and control mice. In some 
experiments, a highly selective CCR2 chemokine receptor antagonist RS504393 (5 mg/kg; 
R&D Systems) or its vehicle alone (DMSO) was injected intraperitoneally 30 min before the 
cheek injection of CCL2 in CHS mice(Miller et al., 2012). Each chemical injected was 
previously prepared and then coded by a laboratory assistant and not the experimenter. The 
experimenter who injected the chemical was blinded to the code and thus the chemical 
injected, as was the observer who scored the video-recorded behavior.  
2.4. Reverse transcription and quantitative RT-PCR 
Ipsilateral L3 to L5 lumbar DRG were harvested 24 hours after the second challenge in 
CHS mice and in acetone treated controls and flash-frozen in liquid nitrogen. Total RNAs 
were extracted using Trizol reagent (Invitrogen, Grand Island, NY, USA) and reverse 
transcribed using PrimeScript™ RT Master Mix (Takara, Japan) according to the 
manufacturer’s instructions. Quantitative RT-PCR (qRT-PCR) was performed on a Bio-Rad 
CFX96 machine using SYBR Premix Ex Taq (Takara, Japan). The primers used were as 
follows: CCL2 forward, 5’-AGG TCC CTG TCA TGC TTC TG-3’ and reverse, 5’- TCA 
TTG GGA TCA TCT TGC TG -3’(Kiguchi et al., 2013); CCR2 forward, 5’-CTC AGT TCA 
TCC ACG GCA TA-3’ and reverse, 5’- CAA GGC TCA CCA TCA TCG TA -3’(Kiguchi et 
al., 2013); GAPDH forward, 5’-CCA TGA CAA CTT TGG CAT TG -3’ and reverse, 5’-CCT 
GCT TCA CCA CCT TCT TG -3’. The expression levels of the target genes were quantified 
  
relative to the level of GAPDH gene expression using the 2
-∆∆CT
 method. Real-time PCR 
experiments for each gene were performed on three separate occasions. 
2.5. Western blotting 
Ipsilateral L3 to L5 lumbar DRG, tissue samples of hairy skin of the calf (calf model) and 
TG (cheek model) were harvested 24 hours after the second challenge in CHS mice and in 
acetone treated controls and then homogenized in the RIPA lysis buffer (CWBio, Beijing, 
China) containing a mixture of protease inhibitors (CWBio). The protein concentrations of 
the lysate were measured using a PierceTM BCA Protein Assay kit (Thermo Scientific, 
Rockford, IL, USA). Equal amounts of protein samples were loaded and separated in 12% 
SDS-PAGE gel and subsequently transferred to PVDF membranes (GE Healthcare, 
Pittsburgh, PA, USA). After blocked in PBST with 5% nonfat dry milk for 2 h at room 
temperature, the membranes were incubated overnight at 4˚C with mouse-anti-CCL2 (1:1000, 
Millipore, Burlington, MA, USA), rabbit-anti-CCR2 (1:1000, Abcam, Cambridge, MA, USA) 
or mouse-anti-GAPDH (1:1000, ZSGB-Bio, Beijing, China) primary antibodies. The 
membranes were then incubated with HRP-conjugated goat anti-mouse (1:3000, ZSGB-Bio) 
or HRP-conjugated goat anti-rabbit (1:3000, ZSGB-Bio) secondary antibodies for 1 h at room 
temperature. Signals were finally detected using eECL Western Blot Kit (CWBio), and the 
bands were visualized with the Amersham Imager 600 (GE Healthcare, Pittsburgh, PA, USA).  
2.6. Immunohistochemistry 
Immunofluorescent labeling was performed on DRGs (calf model) and TGs (cheek model) 
from 3 acetone treated control mice and 3 SADBE treated CHS mice (24 hours after the 
  
second challenge) using the method described previously(Jiang et al., 2017; Liu et al., 2017): 
Briefly, the L3 to L5 DRGs and TGs were harvested from control and CHS mice 
transcardially perfused with PBS followed by 4% paraformaldehyde, post-fixed in the same 
fixative for 2 h, and then cryoprotected in 30% sucrose overnight. The tissue was frozen and 
sectioned at 12 µm thick on a cryostat. Tissue sections were permeabilized with 0.2% Triton 
X-100 in PBS for 15 min, then incubated with blocking buffer (10% normal horse serum) for 
1 h, followed by overnight incubation at 4˚C with primary antibodies (mouse-anti-CCL2, 
1:200, Millipore; rabbit-anti-CCR2, 1:200, Abcam; guinea pig anti-PGP9.5, 1:400, Abcam; 
guinea pig anti-TRPV1, 1:400, Abcam) and then with the proper secondary antibodies (Alexa 
Fluor 488-conjugated donkey anti-mouse, 1:400; Alexa Fluor 488-conjugated donkey 
anti-rabbit, 1:400; Alexa Fluor 594-conjugated donkey anti-guinea pig, 1:400, Invitrogen) for 
1 h. Alexa Fluor 594-conjugated IB4 (1:400, Invitrogen) was added with the secondary 
antibodies. The slides were then washed in PBS and cover-slipped with VECTASHIELD 
Mounting Medium with DAPI (Vector Laboratories, Burlingame, CA, USA). The cells were 
visualized and the images were captured using a laser confocal microscopic imaging system 
(FV1000 and Olympus FluoView software, Olympus，Japan). Here, the dissociated DRG and 
TG neurons in adult mice are categorized into small- (10–25 µm), medium- (25–35 µm) and 
large-sized (>35 µm) based on somal diameter. After taking into account the approximately 
10% decrease in size because of the fixation procedure, DRG and TG neurons were classified 
as small- (area < 442 µm
2
), medium- (area 443–865 µm2) and large-sized (area >865 µm2) 
according to their cross-sectional areas. Only neurons with nucleus profile in the 
cross-section were counted and data from L3 to L5 DRGs were pooled throughout the study. 
  
2.7. Retrograde labeling of cutaneous neurons 
For the in vitro experiments, DiI (Invitrogen), a red fluorescent dye, was injected 
intradermally at a dose of 1.7 mg/mL in 1% DMSO into the hairy skin of the calf and foot of 
one hind limb of mice at 3 sites (10 µL per site) at least 1 week before the first challenge with 
SADBE or acetone vehicle. The label was retrogradely transported to the DRG and 
subsequently used to identify small-diameter, cutaneous DRG neurons innervating the area of 
CHS (or vehicle treatment). 
2.8. Acute culture of dorsal root ganglion neurons 
DRG neurons were acutely cultured as previously described(Qu et al., 2015). Briefly, L3 
to L5 lumbar DRG, ipsilateral to either acetone control or SADBE-treated skin, were 
harvested from mice 24 h after the second SADBE challenge or application of acetone 
vehicle and placed in oxygenated complete saline solution (CSS) for cleaning and mincing. 
The CSS contained (mM): 137 NaCl, 5.3 KCl, 1 MgCl2, 3 CaCl2, 25 sorbitol, and 10 HEPES, 
adjusted to pH 7.2 with NaOH. The DRG were then digested with Liberase TM (0.35 U/ml; 
Roche Diagnostics Corp., Indianapolis, IN, USA) for 20 min, and for another 15 min with 
Liberase TL (0.25 U/ml; Roche Diagnostics Corp.) and papain ((30 U/mL; Worthington 
Biochemical, Lakewood, NJ, USA) in CSS containing 0.5 mM EDTA at 37 ˚C. After 
enzymatic digestion, the cells were dissociated by gentle trituration in DMEM medium 
containing 1 mg/ml bovine serum albumin (Sigma) and 1 mg/ml trypsin inhibitor (Sigma), 
and placed on poly-D-lysine/laminin coated glass coverslips (BioCoat; BD Biosciences, San 
Jose, CA, USA). The DMEM medium contained equal amounts of DMEM and F12 (Gibco, 
  
Grand Island, MD, USA) with 10% FCS (Gibco) and 1% penicillin and streptomycin 
(Invitrogen). The cells were maintained at 37 ˚C in a humidified incubator of 95% air and 5% 
CO2 and used within 24 h. 
2.9. Calcium imaging 
Calcium imaging was performed on the small-diameter (≤25 µm) DiI-labeled DRG 
neurons as described previously(Qu et al., 2015; Qu et al., 2011b). Briefly, DRG neurons 
were loaded with 2 µM Fura 2-acetoxymethyl ester (Invitrogen) in the dark at 37 °C. After 
loading for 45 min, DRG neurons were washed twice with a HEPES buffer to remove 
extracellular dye. The HEPES buffer contained the following (in mM): NaCl 145, KCl 3, 
CaCl2 2, MgCl2 2, glucose 10 and HEPES 10, adjusted to pH 7.4 with NaOH. In some 
experiments, DRG neurons were then incubated with 10 µg/mL isolectin B4 conjugated to 
fluorescein isothiocyanate (IB4–FITC; Sigma) for 10 min, washed in HEPES buffer, and 
visualized with FITC filters. Only neurons with a complete ring of FITC stain around the 
perimeter of the soma were considered as IB4-positive neurons (IB4
+
). Ratiometric calcium 
imaging was performed at room temperature of 20 to 22˚C using an upright Olympus 
BX-51WI microscope equipped with a ratiometric imaging system (INDEC Biosystems, CA, 
USA). The calcium signals by 340 and 380 nm excitation (switched by the monochromator, 
Polychrome V, TILL Photonics, Hillsboro, OR) were recorded at 2-s intervals using a cooled 
CCD camera (SensiCAM, PCO, Germany) controlled by a computer with Image Workbench 
5.2 software (INDEC Biosystems, CA, USA). The ratio of 340 nm/380 nm fluorescence 
intensity (R340 /380) within a certain region of interest was used as a relative measure of 
intracellular calcium concentration ([Ca
2+
]i)(Grynkiewicz et al., 1985). All agents were 
  
dissolved in HEPES buffer and applied locally to the neuronal cell bodies through a 
micropipette with a tip diameter of 100 µm and a 8-channel pressure-controlled drug 
application system (AutoMate Scientific, Berkeley, CA, USA). Mouse recombinant CCL2 
(50 nM)(Oh et al., 2001) or RS504393 (10 µM in 0.1% DMSO) (Mirzadegan et al., 2000; 
Zhou et al., 2011)was added to HEPES buffer. Histamine (His; 100 µM; 30 s) or capsaicin 
(CAP; 1 µM; 10 s), was applied to identify His- and CAP-sensitive nociceptors, respectively. 
At the end of each experiment, the viability of the neurons was confirmed by the increase in 
[Ca
2+
]i induced by a 5 s application of 50 mM K
+
. Neurons were considered to respond to a 
chemical if an increase in [R(340/380)] was equal or greater than 15% above baseline(Wilson et 
al., 2011). The proportion of DRG neurons responsive to a chemical was calculated as the 
number of chemically-responsive neurons divided by all the neurons tested. Only Dil-labeled 
cutaneous small-diameter neurons (≤25 µm) that innervated the chemically treated areas were 




 neurons that innervated the epidermis 
were additionally labeled by a GFP(Han et al., 2013b; Qu et al., 2014). 
2.10. Whole-cell patch-clamp recordings 
Whole-cell current-clamp recordings were made on small-diameter (≤25 µm) DiI-labeled 
DRG neurons using a MultiClamp 700A amplifier and pCLAMP 9 software (Molecular 
Devices, Sunnyvale, CA, USA), as described(Qu et al., 2011a; Qu et al., 2015; Qu et al., 
2012). Signals were sampled at 10 kHz or 20 kHz and filtered at 2 kHz. The patch pipettes 
were pulled from borosilicate glass capillaries (Sutter Instruments, Novato, CA, USA; 1.2 
mm outer diameter, 0.69 mm inner diameter) with a P97 horizontal puller (Sutter 
Instruments). The resistance of the patch pipettes was 3-4 MΩ after filled with an internal 
  
solution, the liquid junction potentials were corrected and the series resistance was routinely 
compensated at 60% to 80%. The internal solution contained the following (in mM): 
K
+
-gluconate 120, KCl 30, MgCl2·6H2O 2, HEPES 10, MgATP 2, CaCl2·2H2O 1, EGTA 11, 
with an osmolarity of 290-300 mOsm and a pH that was adjusted to 7.2 using Tris base. The 
DRG neurons were continuously perfused with the HEPES buffer and all the recordings were 
performed at a room temperature of 20 -22 °C. The resting membrane potential (RMP) of 
each neuron was recorded after stabilization within 3 min. A neuron was studied only if its 
RMP was more negative than -45 mV. Action potentials (APs) were evoked by a series of 
depolarizing current steps, each of 500 ms duration, in increments of 50 pA up to 1 nA. The 
current threshold (rheobase) was defined as the minimal depolarizing current required to 
evoke an AP. The input resistance was obtained from the slope of a steady-state 
current–voltage plot in response to a series of hyperpolarizing currents steps from -200 to -50 
pA, each step 500 ms in duration. 
2.11. Statistical analyses 
Data values were presented as means ± SEMs. Statistical analyses were performed using 
the SPSS software (version 17.0). A Student’s t-test was used to test the statistical 
significance of a difference between mean responses for two groups. Chi-square tests were 
used to compare the incidence of neuronal responses. The criterion for statistical significance 




3.1. CHS upregulated neuronal expression of CCL2 and CCR2  
The mean levels of mRNA expression for CCL2 and CCR2 were significantly greater in 
the DRG from CHS mice compared with those from control mice treated only with acetone 
(Fig. 1A). From analyses with Western blot, the protein levels of CCL2 and CCR2 were 
significantly upregulated in the DRG in CHS mice compared with that in control mice (Fig. 
1B and C). Immunofluorescent staining revealed very few CCL2- and CCR2-immunopositive 
DRG neurons in control mice (Fig. 1D, G and H). In contrast, the mean percentage of CCL2- 
and CCR2-immunopositive DRG neurons was significantly greater in CHS mice (Fig. 1D, I 
and J). Based on our categorizations of neuronal size (see Methods), 87.0% of 
CCL2-immunopositive DRG neurons after CHS were classified as small, 13.0% were 
medium, and none were large (Fig. 1E). CCR2 was found expressed in all size categories of 
DRG neurons in CHS mice with 76.3% of CCR2-immunopositive DRG neurons classified as 
small, 21.3% as medium and only 2.5% as large (Fig. E). In addition, some 
CCR2-immunopositive DRG neurons were also immunopositive for the nociceptive neuronal 
markers IB4 (detected in 55.8% of neurons with CCR2-immunopositive, Fig. 1K) and 
TRPV1 (56.7.0%, Fig. 1L). 
3.2. CHS increased the incidence and magnitude of CCR2-mediated Ca
2+
 responses to 
CCL2 in cutaneous DRG neurons  
CCL2 (50 nM; 2 min) applied locally to the neuronal cell bodies caused a [Ca
2+
]i increase 
in few cutaneous DRG neurons from control mice (Fig. 2A, C). However, there were 
significantly more neurons responding to CCL2 in CHS mice (Fig. 2B, C). Furthermore, the 
mean magnitude of CCL2-evoked Ca
2+
 responses was significantly greater in neurons for 
  
CHS than control mice (Fig. 2D). Among CCL2-responsive neurons from CHS mice, 80.6% 
(50 of 62) and 75.8% (47 of 62) responded to histamine (His, 100 µM) and capsaicin (CAP, 1 
µM) with an increase in [Ca
2+
]i, respectively (Fig. 2B). When the neurons incubated with 10 








 neurons were previously found to contribute to pain- and/or 
itch-related behavior associated with CHS(Han et al., 2013b; Qu et al., 2014; Qu et al., 2015). 





 receptors (Fig. 2E, G) and the magnitude of their 
responses (Fig. 2F, H) were significantly greater in CHS than control mice. These data 




pruriceptive nociceptors express functional 
CCR2 receptors and can be directly activated by CCL2 after CHS. 
To examine the role of neuronal CCR2 in the CCL2-evoked [Ca
2+
]i responses, DRG 
neurons were pretreated with a specific CCR2 antagonist, RS504393 (10 µM in 0.1% DMSO 
vehicle), for 3 min(Mirzadegan et al., 2000; Wang et al., 2010; Zhou et al., 2011). In the 
presence of RS504393, the percentage of CCL2-responsive neurons was significantly 
reduced compared with the effects of vehicle alone (Fig. 3A-C). Furthermore, the mean 
magnitude of CCL2-evoked Ca
2+
 responses was significantly attenuated by RS504393 but 
not by vehicle alone (Fig. 3D). These results suggest that neuronal CCR2 mediated the 
CCL2-induced [Ca
2+
]i responses in DRG neurons.  
3.3. CCL2 increased the membrane excitability of dorsal root ganglion neurons 
innervating CHS skin through neuronal CCR2. 
  
Whole-cell current-clamp recordings were performed on DiI-labeled small-diameter DRG 
neurons from CHS mice and acetone-treated control mice. The local application of CCL2 (50 
nM; 2 min) but not vehicle, depolarized more cutaneous DRG neurons (Fig. 4B, C and D) 
from CHS- than from control mice (Fig. 4B). Moreover, Four of 11 responsive neurons 
(36.3%) from CHS mice exhibited action potential (AP) discharges (Fig. 4A). The local 
application of CCL2 significantly decreased the rheobase (Fig. 4F) and the input resistance 
(Fig. 4E), suggesting an increase in the opening of resting ion channels. Pretreatment with 
RS504393 (10 µM) for 3 min decreased the percentage of CCL2-responsive neurons (Fig. 
4H). Furthermore, in the presence of RS504393, the CCL2-induced membrane depolarization 
was significantly attenuated and no AP discharges was evoked for these responsive neurons 
(Fig. 4G, I). These results indicate that neuronal CCR2 mediates the direct excitatory effect 
of CCL2 on primary sensory neurons after CHS. 
3.4. CCL2 and CCR2 mediated itch- and pain-like behaviors in CHS mice. 
The cheek model was used to investigate the behavioral effects of CCL2 in CHS(Shimada 
and LaMotte, 2008b). Consistent with the expression pattern of DRG neurons in the calf 
model, CCR2 was significantly upregulated in TG neurons innervating the cheek (Fig. S1). 
At 24 hours after the second challenge, consistent with our previous studies(Qu et al., 2014; 
Qu et al., 2015), mice challenged with SADBE displayed a significant increase in the number 
of spontaneous site-directed bouts of scratching and number of wipes as compared with 
acetone-treated control mice (Fig. 5A and B). Intradermal injection of CCL2 (1 μg/10 μl) into 
the cheek of CHS mice induced more scratching bouts and more wipes in comparison with 
the injection of vehicle (PBS) (Fig. 5A and B). In contrast, CCL2 injected into the acetone 
  
control cheek evoked the same amount of scratching and wiping as an injection of PBS 
vehicle alone (Fig. 5A and B). Moreover, intraperitoneal pre-injection of RS504393 (5 
mg/kg), a highly selective CCR2 chemokine receptor antagonist, but not its vehicle (DMSO), 
completely inhibited the scratching and wiping evoked by CCL2 injected in CHS mice (Fig. 
5B, D). These results suggest that CCL2 mediates itch and pain behaviors through CCR2 in 
vivo under inflammatory skin conditions. 
 
4. Discussion 
In this study, we first demonstrated that CHS upregulated CCL2/CCR2 signaling in 
cutaneous primary sensory neurons, that CCL2 could directly activate CCR2 expressed on 
cutaneous small-diameter primary sensory neurons, and that an injection of CCL2 into the 
CHS site evoked itch- and pain-like behaviors. 
CCL2 and CCR2 are widely expressed in the immune system and not expressed at high 
levels in the normal nervous system. However, the synthesis of CCL2 and CCR2 can be 
significantly up-regulated in primary sensory neurons under pathological conditions(Abbadie 
et al., 2003; Bhangoo et al., 2007; Jeon et al., 2008; Jung et al., 2009; Tanaka et al., 2004; 
White et al., 2005; Zhang and De Koninck, 2006). For example, CCL2 and CCR2 are 
up-regulated in primary sensory neurons after a chronic compression of the DRG (CCD)(Sun 
et al., 2006; White et al., 2005). In the present study mRNA and protein expression levels of 
CCL2 and CCR2 were both significantly increased in DRG after the development of CHS. 
CCL2 was also significantly upregulated in the inflamed skin (Fig. S2) as found in previous 
studies and attributed to its release from activated resident skin cells and monocytes(Goebeler 
  
et al., 2001; Mitsui et al., 2003; Sebastiani et al., 2002; Yu et al., 1994). The present 
upregulation of neuronal CCL2 is consistent with the hypothesis that the chemokine may be 
released from the peripheral terminals of DRG neurons in the area of CHS.  
There was a significantly greater percentage of primary sensory neurons expressing not 
only CCL2 but also CCR2 after CHS. Although CCR2 was found in all size categories of 
primary sensory neurons, it was mainly presented in small-diameter neurons as well as CCL2. 
Notably, the expression pattern of CCR2 in primary sensory neurons may be different in 
different types of pathology. In an animal model of Paclitaxel (chemotherapy-induced 
peripheral neuropathy), CCR2 was strongly upregulated in DRG neurons of large- and 
medium-size but not small size whereas CCL2 was mainly expressed in small nociceptive 
neurons(Zhang et al., 2013). In the present study, CCL2-responsive neurons had 
characteristics of nociceptors as evidenced by their expression of IB4
+
 and TRPV1 or their 
calcium responses to capsaicin. Some of the neurons responsive to CCL2 after CHS were 
pruriceptive nociceptors that expressed MRGPRA3 or MRGPRD. These neurons are known 
to respond to one or more pruritic chemicals such as chloroquine, histamine and BAM8-22 
(MRGPRA3
+ 
neurons)(Han et al., 2013b) or β-alanine (MRGPRD+ neurons)(Liu et al., 2012).  
ACD (CHS) is an inflammatory skin disease orchestrated by proinflammatory mediators. 
Some of these mediators include cytokines that, under various conditions, activate 
transcription factors that increase in the synthesis of CCL2 and/or CCR2 in peripheral 
sensory neurons(Glabinski et al., 2003; Jung and Miller, 2008; Subang and Richardson, 2001; 
Tofaris et al., 2002; Ueda et al., 1994). CCL2 in DRG neurons is packaged into large 
dense-core vesicles (LDCVs) whose release could be induced from the soma by 
  
depolarization in a Ca
2+
-dependent manner(Jung et al., 2008). Possibly the presence of CCL2 
in the DRG could result in the upregulation of TRPV1 and the voltage-gated sodium channel, 
Nav1.8(Kao et al., 2012). However, the mechanisms for the synthesis, release and effects of 
CCL2 in the DRG after CHS will require further investigation. 
CCL2 depolarized and sometimes evoked action potentials discharge in neurons that 
innervated the site of CHS but rarely so in neurons that had innervated healthy, control skin. 
The ionic mechanisms underlying CCL2-induced neuronal activation have been well studied. 
CCL2 excites CCD-treated neurons through the activation of a non-voltage-dependent 
depolarizing current with characteristics similar to a nonselective cation conductance and 
through the inhibition of a voltage-dependent outward current(Sun et al., 2006). CCR2 is a G 
protein-coupled receptor. CCL2, binding to CCR2, leads to the activation of PLC, which is 
critical for the increase in intracellular calcium ([Ca
2+
]i)(White et al., 2005). Some studies 
reported that this activation of CCR2 by CCL2 could excite DRG neurons via transactivation 
of TRRV1 and TRPA1(Jung et al., 2008). 
Previous studies have shown that CCL2 is involved in the pathogenesis of CHS, but not 
whether the chemokine contributes to the itch and pain that accompany this disorder. In the 
present study, we observed that an intradermal injection of CCL2 into the site of CHS 
significantly elicited site-directed itch- and pain-like behaviors. Neither type of CCL2-evoked 
behaviors was observed in control mice. In addition, the exogenous CCL2-evoked itch- and 
pain-like behaviors were almost abolished by an antagonist of CCR2. Itch and pain are 
normally initiated and mediated by primary nociceptive neurons. It is clear that CCL2 can 
directly activate primary nociceptors through neuronal CCR2 to elicit and/or maintain certain 
  
types of neuropathic or inflammatory pain(Miller et al., 2012; Serrano et al., 2010; Sun et al., 
2006; Takeda et al., 2018; White et al., 2005). There was evidence that MrgprA3
+
 neurons 
were needed for normal histamine-dependent itch behavior(Han et al., 2013a), MrgprD
+
 
neurons contribute to mechanically evoked pain but also to the histamine-independent itch 
evoked by β-alanine(Cavanaugh et al., 2009; Liu et al., 2012). Furthermore, both types of  
pruriceptive neurons displayed enhanced excitability after CHS(Qu et al., 2014). The present 
study from in vitro calcium imaging and electrophysiological recordings demonstrated that 
the activation of neuronal CCR2 by CCL2 can directly excite cutaneous sensory neurons with 
nociceptive and pruriceptive properties. Therefore, our findings suggest that CCL2 directly 
activates neuronal CCR2 to induce itch- and pain-like behaviors in the context of CHS. 
Because CCR2 is expressed in immune cells including macrophages, dendritic cells, T 
cells and NK cells, CCL2 binding to CCR2 in the peripheral tissue might indirectly activate 
primary sensory neurons through the release of proinflammatory cytokines from immune 
cells(Allavena et al., 1994; Carr et al., 1994; Loetscher et al., 1994). Furthermore, our 
previous study revealed that the upregulation of CXCL10/CXCR3 signaling in sensory 
neurons may contribute to itch associated with CHS(Qu et al., 2015). These chemokines may 
work together to contribute to the itch and pain accompanying CHS in mice and in humans 
by directly exciting primary sensory neurons through their neuronal receptors and/or 
indirectly activating immune cells to induce the release of inflammatory mediators that target 
primary sensory neurons. 
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Figure 1. Upregulation of the expression of CCL2 and CCR2 in the DRG in CHS mice. A. 
qRT-PCR revealed a significant increase in mRNA expression levels of CCL2 and CCR2 in 
L3-L5 DRG for CHS (SADBE- treated) vs control (vehicle-treated) mice 24 hours after the 
second challenge (n=5 mice/group for CCL2, n=3 mice/group for CCR2). B. Western blot 
revealed a significant increase in the levels of CCL2 and CCR2 protein expression in L3-L5 
DRG for CHS vs control mice 24 hours after the second challenge (n=3 mice/group). C. The 
representative gel bands of CCL2 and CCR2 protein from control and CHS mice. D. 
Immunofluorescence staining showed a significantly higher percentage of CCL2- and 
CCR2-immunopositive DRG neurons in CHS mice compared with that in control mice (n=3 
mice/group). E. Frequency distribution of different cell sizes of 
CCL2/CCR2-immunopositive DRG neurons in CHS mice. F. Percentages of CCR2 positive 
DRG neurons that express IB4 and TRPV1 in CHS mice. G-J. Typical microscopic images of 
immunofluorescence staining for CCL2 (G and I) and CCR2 (H and J) from control and CHS 
mice. K and L. CCR2 was found co-expressed with IB4 (K) and TRPV1(L) in some DRG 
neurons in CHS mice. Arrows indicate immunopositive neurons. Scale bar: 25 µm. *p < 0.05, 
***p < 0.001, CHS vs control, Student’s t-test. 
 
Figure 2. CHS increased the incidence and magnitude of CCL2-induced Ca
2+
 responses in 
DRG neurons with pruriceptive or nociceptive properties. A and B. Cultured cutaneous 
(DiI-labeled) DRG neurons isolated from control (A) and CHS (B) mice were exposed to 
  
CCL2 (50 nM, 2 min), followed by histamine (His; 100 µM, 30 s), capsaicin (CAP; 1 µM, 10 
s) and KCl (50 mM, 5 s), and analyzed by Fura-2 ratiometric calcium imaging (representative 
traces). Black bars above the traces show the duration of chemical application. C and D. The 
proportion of CCL2-responsive cutaneous DRG neurons and the mean magnitude of 
CCL2-induced Ca
2+
 response were significantly higher for CHS mice than for acetone-treated 
control mice. E and F. The percentage of MrgprA3
+
 neurons that responded to CCL2 and the 
mean magnitude of Ca
2+
 signal in the responsive neurons were significantly greater in CHS 
than that in control mice. G and H. The percentage of MrgprD
+
 neurons that responded to 
CCL2 and the mean magnitude of Ca
2+
 signal in the responsive neurons were significantly 
greater in CHS than that in control mice. Numbers of neurons tested are given in parentheses. 
**p < 0.01 versus control, Chi-square test (C, E and G); *p < 0.05 versus control, Student’s 
t-test (D, F and H). 
 
Figure 3. Neuronal CCR2 is required for CCL2-induced [Ca
2+
]i responses in cutaneous DRG 
neurons. A and B. Representative traces of Ca
2+
 responses evoked by CCL2 (50 nM, 2 min) 
in the presence of a specific CCR2 antagonist RS504393 (10 µM in a vehicle of 0.1% DMSO) 
vs in the presence of the vehicle alone. C and D. The percentage of CCL2-responsive 
neurons and the mean magnitude of CCL2-evoked Ca
2+
 response were significantly 
attenuated by pretreatment with RS504393 but not vehicle. The neurons tested were all from 
CHS mice. The numbers of neurons tested are given in parentheses. *p < 0.05 versus vehicle, 
Chi-square test (C); *p < 0.05 versus vehicle, Student’s t-test (D). 
 
  
Figure 4. CCL2 increased the excitability of cutaneous DRG neurons after CHS. A and D. 
Representative whole-cell current-clamp recordings of CCL2-induced membrane potential 
depolarization with (A) and without (D) AP discharges. Black bars above the traces show the 
timing of CCL2 (50 nM; 2 min) application. B. The percentage of neurons responsive to 
CCL2 during whole-cell current-clamp recordings in CHS mice and acetone-treated control 
mice. C, E and F. Mean resting membrane potential, input resistance, and rheobase during 
application of vehicle (HEPES buffer) and CCL2 in cutaneous DRG neurons from CHS mice. 
G. Typical whole-cell current-clamp recordings during CCL2 application in the presence of 
RS504393 (10 μM). H and I. Pretreatment with RS504393 decreased the percentage of 
neurons that responded to CCL2 (H) and significantly reduced the mean magnitude of 
CCL2-induced membrane depolarization (I). Numbers of neurons responding and/or tested is 
given in parentheses. *p < 0.05, **p < 0.01 versus vehicle, paired t test (C, E and F); *p < 
0.05 versus control, Student’s t-test (I). 
 
Figure 5. CCL2/CCR2 signaling mediated itch- and pain-like behaviors in CHS mice. A and 
B. The effects of CHS on the cheek on spontaneous and CCL2-evoked site-directed 
scratching and wiping (itch- and pain-like behaviors, respectively) 24 hours after the second 
challenge with SADBE (CHS, closed bars) or acetone vehicle (control, open bars). CHS mice 
displayed a significant increase in site-directed scratching and wiping compared with control 
mice. Intradermal injection of CCL2 (1 μg/10 μl in PBS vehicle) into the cheek of CHS mice 
significantly increased the site-directed scratching (A) and wiping (D) compared with the 
effects of injecting the PBS vehicle alone (Veh1). When CCL2 was injected into the cheek of 
  
control mice, there were no significant differences in effects from injecting PBS vehicle alone. 
The CCL2-evoked scratching and wiping in the cheek challenged with SADBE was 
significantly reduced by intraperitoneal pre-injection of RS504393 (5 mg/kg) but not its 
DMSO vehicle (Veh2). There were no significant differences (ns) in either scratching bouts 
or number of wipes between PBS (Veh1)-treated and RS504393-treated CHS mice. The 



















 Contact hypersensitivity (CHS), a murine model of allergic contact dermatitis,  
upregulated CCL2/MCP-1 and CCR2 in nociceptors. 
 
 CCL2 injected into CHS site evoked site-directed itch- and pain-like behaviors. 
 
 CCL2 activated nociceptive dorsal root ganglion neurons innervating CHS site. 
. 
 A CCR2 antagonist decreased these behavioral and neuronal responses. 
  
 Targeting CCL2/CCR2 signaling might treat allergic itch and pain in humans. 
 
 
